What is ACCURE Therapeutics?
Headquartered in Barcelona, ACCURE Therapeutics is a specialized translational neuroscience R&D enterprise established in 2020. The company distinguishes itself through a unique portfolio of three new chemical entity programs, designed to address unmet medical needs in the CNS space. Unlike traditional pharmaceutical firms that may be tethered to specific research methodologies, ACCURE employs an agnostic scientific framework, enabling the team to pivot and optimize drug candidates based on emerging clinical data. This operational agility, combined with a seasoned leadership team, allows the company to bridge the gap between early-stage discovery and late-stage clinical validation, effectively de-risking its pipeline for future commercialization.
How much funding has ACCURE Therapeutics raised?
ACCURE Therapeutics has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2025): $1.6M with participation from The Michael J Fox Foundation and The FNR
Key Investors in ACCURE Therapeutics
The Michael J Fox Foundation
A leading non-profit organization dedicated to accelerating Parkinson's disease research and developing improved therapies for patients worldwide.
The FNR
The Luxembourg National Research Fund acts as the primary public funding agency, supporting high-impact scientific research and international cooperation across various disciplines.
What's next for ACCURE Therapeutics?
With the recent influx of capital, ACCURE Therapeutics is poised to transition its lead programs into more advanced stages of development. The strategic roadmap involves intensifying clinical trial activities and expanding the company's intellectual property portfolio. By leveraging its current financial stability, the firm aims to strengthen its collaborative efforts with international research institutions and regulatory bodies. The focus remains on achieving key clinical milestones that will validate the efficacy of its novel chemical entities, ultimately paving the way for potential licensing agreements or strategic partnerships with larger pharmaceutical entities looking to bolster their neurology portfolios.
See full ACCURE Therapeutics company page
